Conduit Pharmaceuticals Selects Initial Indications for Lead Clinical Candidate Targeting Autoimmune Disorders

Conduit Pharmaceuticals, Inc. announced the selection of initial indications for its lead clinical candidate, HK-4 glucokinase activator AZD1656 licensed from AstraZeneca. Conduit intends to initiate Phase IIa clinical trials to evaluate AZD1656 for the treatment of systemic lupus erythematosus and ANCA-associated vasculitis.